ArticleJournal of virology2011
Differential sensitivities of retroviruses to integrase strand transfer inhibitors.
Article in Journal of virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Non-integrase mechanisms for dolutegravir resistance.Retrovirology · 2026Review
- Structure and function of retroviral integrase.Nature reviews. Microbiology · 2022Review
- Combination antiretroviral therapy improves recurrent primary biliary cholangitis following liver transplantation.Liver international : official journal of the International Association for the Study of the Liver · 2021Article
- Cryo-EM structure of the Rous sarcoma virus octameric cleaved synaptic complex intasome.Communications biology · 2021Article
- Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.The FEBS journal · 2021Review
- HIV‑1 integrase inhibitors targeting various DDE transposases: Retroviral integration versus RAG‑mediated recombination (Review).Molecular medicine reports · 2019Review
- Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.The Journal of biological chemistry · 2019Review
- Genetic Strategies for HIV Treatment and Prevention.Molecular therapy. Nucleic acids · 2018Review
- Article
- Retroviral integrase protein and intasome nucleoprotein complex structures.World journal of biological chemistry · 2017Review
- Retroviral DNA Integration.Chemical reviews · 2016Review
- Susceptibility of porcine endogenous retrovirus to anti-retroviral inhibitors.Xenotransplantation · 2016Article
- Rous sarcoma virus synaptic complex capable of concerted integration is kinetically trapped by human immunodeficiency virus integrase strand transfer inhibitors.The Journal of biological chemistry · 2014Article
- Structural basis of Mos1 transposase inhibition by the anti-retroviral drug Raltegravir.ACS chemical biology · 2014Article
- Enhanced autointegration in hyperstable simian immunodeficiency virus capsid mutants blocked after reverse transcription.Journal of virology · 2013Article
- Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents.Journal of virology · 2013Article
- Development of a robust cell-based high-throughput screening assay to identify targets of HIV-1 viral protein R dimerization.Drug design, development and therapy · 2013Article
- Multiple choices for HIV therapy with integrase strand transfer inhibitors.Retrovirology · 2012Article
- The structural biology of HIV-1: mechanistic and therapeutic insights.Nature reviews. Microbiology · 2012Review
- Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Integrase inhibitors are emerging anti-human immunodeficiency virus (HIV) drugs, and multiple retroviruses and transposable elements were evaluated here for susceptibilities to raltegravir (RAL) and elvitegravir (EVG). All viruses, including primate and nonprimate lentiviruses, a Betaretrovirus, a Gammaretrovirus, and the Alpharetrovirus Rous sarcoma virus (RSV), were susceptible to inhibition by RAL. EVG potently inhibited all lentiviruses and intermediately inhibited Betaretrovirus and Gammaretrovirus infections yet was basically ineffective against RSV. Substitutions based on HIV type 1 (HIV-1) resistance changes revealed that integrase residue Ser150 contributed significantly to the resistance of RSV. The drugs intermediately inhibited intracisternal A-particle retrotransposition but were inactive against Sleeping Beauty transposition and long interspersed nucleotide element 1 (LINE-1) retrotransposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.